Immunome (NASDAQ:IMNM) Sets New 12-Month High - Should You Buy?
Immunome (NASDAQ:IMNM) recently hit a new 52-week high of $29, with a market capitalization of $3.38 billion, despite missing quarterly earnings expectations. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and a $34.64 price target, though insiders have been selling shares while institutional investors hold 44.58% of the stock. The company is a clinical-stage biotechnology firm focused on developing antibody-based therapeutics for oncology and infectious diseases.
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration
Immunome (IMNM) is facing investor scrutiny after reporting wider net losses and filing a shelf registration, despite a significant 1-year stock return of 173.45%. The company's valuation presents conflicting signals, with a Price-to-Book ratio of 5.9x suggesting overvaluation compared to peers, while a Discounted Cash Flow model indicates it's trading 76.3% below its estimated fair value. Investors are left to weigh high growth expectations against increased loss and potential dilution.
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration
Immunome (IMNM) is facing a valuation test after reporting wider net losses and filing a new shelf registration to issue more shares, despite a significant stock price increase over the last year. The company's P/B ratio of 5.9x is higher than peers, suggesting investors are betting on its oncology pipeline rather than current earnings, while a DCF model indicates the stock is undervalued. This mixed outlook highlights the need for investors to carefully review underlying data and consider both the potential upside and warning signs.
Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Moderate Buy" from Analysts
Immunome, Inc. (NASDAQ:IMNM) has received an average "Moderate Buy" rating from analysts, with a 12-month average price target of $34.64. Despite this positive outlook, the company missed its quarterly earnings estimates and experienced significant insider selling totaling $15.7 million over the past three months. Institutional investors currently own 44.58% of the stock.
Is Immunome’s (IMNM) Russell Exit Quietly Recasting Its Shareholder Base And Liquidity Story?
Immunome, Inc. (IMNM) was removed from several Russell indices in late June 2026, coinciding with insider stock sales. This exit is expected to significantly impact the company's shareholder base and trading liquidity, making future funding for its pipeline more sensitive to market fluctuations. Despite recent stock price increases, the company faces substantial annual losses and no clear path to profitability, with analyst fair value estimates showing wide disagreement.
Immunome director Isaac Barchas sells $940,453 in common stock
Immunome director Isaac Barchas sold $940,453 worth of the company's common stock in early August 2026 through two transactions executed via a Rule 10b5-1 trading plan. The sales occurred when the stock was trading near its 52-week high, despite an InvestingPro analysis indicating the stock remains undervalued. Mr. Barchas disclaimed beneficial ownership except for his pecuniary interest in the shares, which are held indirectly by AMBHMC II LLC, where he is a managing member.
Dimensional Fund Advisors LP Decreases Stock Position in Immunome, Inc. $IMNM
Dimensional Fund Advisors LP significantly reduced its stake in Immunome, Inc. (NASDAQ:IMNM) by 89.4% in the first quarter, selling 282,975 shares and retaining 33,408 shares valued at $731,000. Despite this reduction and recent insider selling totaling $15.7 million, institutional investors still hold 44.58% of the company. Immunome reported a quarterly loss of $0.65 per share, missing analyst estimates, yet analysts generally maintain a "Moderate Buy" rating with a consensus price target of $34.64.
Immunome (IMNM) Is Up 8.7% After Wider Loss And ESOP Shelf Filing What’s Changed
Immunome (IMNM) shares rose by 8.7% despite the company reporting a wider net loss and increased loss per share for Q2 and the first half of 2026. The biotech firm also filed a US$38.54 million shelf registration for an ESOP-related offering, aiming to maintain financial flexibility for future capital needs. The company's investment narrative continues to center on its desmoid tumor candidate, varegacestat, and early ADC pipeline, with a PDUFA date for varegacestat set for April 2027.
Immunome (NASDAQ:IMNM) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Immunome (NASDAQ:IMNM) to a "strong sell" rating, contrasting with the broader analyst consensus of "Moderate Buy" and a price target of $34.64. This downgrade follows Immunome reporting a quarterly loss of $0.65 per share, missing estimates, with full-year losses expected around $2.30 per share. Insider selling has also occurred, with approximately $15.7 million worth of shares sold by company insiders over the past three months.
T. Rowe Price Investment Management (IMNM) discloses 17.4% Immunome ownership, key fund at 6.5%
T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 17.4% of Immunome, Inc. common stock, totaling 19,676,883 shares, according to a recent SEC filing. The firm holds sole voting power over 19,656,814 shares and sole dispositive power over all 19,676,883 shares. Additionally, its T. Rowe Price Small-Cap Stock Fund holds a 6.5% interest in Immunome, representing 7,179,563 shares.
Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A
Sirenia Capital Management LP and Alex Silverstein have reported a 4.3% beneficial ownership stake in Immunome Inc. (IMNM) through an amended Schedule 13G filing. They collectively hold 4,832,279 shares of common stock, representing 4.3% of the 113,250,394 shares outstanding as of May 7, 2026. The reporting persons have shared voting and dispositive power over these shares, and the filing indicates their stake is below the 5% threshold.
Renaissance Technologies LLC Makes New Investment in Immunome, Inc. $IMNM
Renaissance Technologies LLC has acquired a new stake in Immunome, Inc. (NASDAQ:IMNM), purchasing over 68,000 shares worth approximately $1.5 million. This investment comes as other institutional investors have also increased their holdings in the clinical-stage biotechnology company, which recently reported a wider-than-expected quarterly loss of $0.65 per share. Despite the loss, analyst sentiment remains largely positive, with a "Moderate Buy" rating and an average price target of $34.64.
Immunome (NASDAQ:IMNM) Reaches New 12-Month High Following Analyst Upgrade
Immunome (NASDAQ:IMNM) shares hit a new 52-week high of $28.04 after Truist Financial raised its price target to $38 from $37, maintaining a "Buy" rating. Despite a larger-than-expected quarterly loss and significant insider selling, analyst sentiment remains largely positive, with a consensus price target of $34.64. The company’s stock closed at $27.99, up from its previous close of $26.25, reflecting investor confidence following the analyst upgrade and progress in its clinical-stage antibody programs.
Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027
Immunome is advancing varegacestat for desmoid tumors after its Phase 3 RINGSIDE study showed an 84% reduction in disease progression or death risk. The FDA has accepted the New Drug Application with a target action date of April 28, 2027, and the company plans to seek approval in Europe by the end of 2026. Immunome is also expanding its oncology pipeline with three additional clinical-stage programs enrolling patients.
Insider Selling: Immunome (NASDAQ:IMNM) Director Sells 11,048 Shares
Immunome (NASDAQ:IMNM) Director Isaac Barchas sold 11,048 shares of the company's stock for over $301,000, reducing his holdings by 10.7%. This sale is part of a series of transactions under a pre-arranged trading plan, totaling about $2.6 million from August 10-12. Despite the sales and Immunome missing its quarterly earnings estimates, analysts maintain a "Moderate Buy" rating with an average price target of $34.64.
Immunome director Isaac Barchas sells over $2.1m in shares By Investing.com
Immunome director Isaac Barchas sold over $2.19 million worth of company shares in August 2026 through pre-arranged Rule 10b5-1 trading plans. These sales included shares held indirectly by AMBHMC II LLC and directly by Barchas, following which he directly holds 92,211 shares. The sales occurred as Immunome's stock is near its 52-week high, despite an InvestingPro analysis suggesting it remains undervalued.
Immunome, Inc. Stock 12‑Month Price Target Raised to $36.31, Implies 38% Upside
Immunome, Inc.'s average 12-month price target has been increased to $36.31 by 13 analysts, up from $35.77, with individual forecasts ranging from $30 to $40 per share. This new target suggests a potential upside of approximately 38% from its August 11 closing price. The consensus rating for Immunome, Inc. remains a "Buy" among 14 analysts.
Immunome stock hits 52-week high at 27.68 USD
Immunome Inc. (IMNM) stock has reached a new 52-week high of $27.68, reflecting significant investor confidence with a 1-year change of 175.42%. Despite InvestingPro analysis suggesting the shares may be overvalued, analysts have revised earnings upwards, with price targets ranging from $30 to $40. Recent company developments, including initiating Phase 1 trials for IM-3050 and IM-1617 and the FDA's acceptance of a New Drug Application for varegacestat, indicate ongoing progress in its therapeutic advancements.
Immunome Inc. SEC Filing (Aug 12, 2026)
This article reports on an Immunome Inc. SEC Filing (Form 144) submitted on August 12, 2026, which details a proposed sale of 11,048 shares of common stock with an aggregate market value of $301,058.00. The filing, accepted by the SEC EDGAR at 11:40 AM on that date, also provides information about the acquisition of these securities on March 30, 2026, as an investment distribution from the issuer.
Immunome Inc. Q2 2026: Revenue $0 Net loss $73.1M, EPS $(0.65) — 10-Q Summary
Immunome Inc. reported Q2 2026 financial results, showing zero revenue and a net loss of $73.1 million, or $(0.65) per diluted share. This is a decline compared to the prior year's Q2 2025, which had $4 million in revenue and a net loss of $43.4 million. The company announced progress in its clinical trials, an increase in R&D investment, and expects its cash reserves to fund operations for at least the next 12 months.
Immunome Inc. Q2 2026: Revenue $0 Net loss $73.1M, EPS $(0.65) — 10-Q Summary
Immunome Inc. reported Q2 2026 results with $0 revenue and a net loss of $73.1 million, or $(0.65) per diluted share, compared to $4 million revenue and a $43.4 million net loss in the prior-year quarter. Key business highlights include the FDA's acceptance of an NDA for varegacestat, clinical progress in multiple drug candidates, and increased R&D investment. The company expects its cash reserves to fund operations for at least 12 months.
Immunome director Isaac Barchas sells over $2.1m in shares
Immunome Inc. director Isaac Barchas sold over $2.1 million worth of company shares in early August 2026 through pre-arranged trading plans. These sales occurred as Immunome's stock traded near its 52-week high, following a significant 182% return over the past year. Despite the sales, an InvestingPro analysis suggests the stock remains undervalued relative to its fair value.
Immunome Q2 Results: EPS Misses Estimate, Losses Widen 30% YoY
Immunome Inc. reported a Q2 2026 net loss of $73.1 million, significantly wider than the previous year, primarily due to increased R&D and administrative expenses, and missed EPS estimates. Despite financial challenges, the company secured FDA acceptance for its varegacestat NDA with a PDUFA date of April 28, 2027, and advanced other oncology pipeline candidates. The company maintains a robust cash position of $520.0 million to fund operations into 2028.
Immunome (NASDAQ:IMNM) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS
Immunome (NASDAQ:IMNM) announced its quarterly earnings, reporting a loss of $0.65 per share, which missed the consensus estimate by $0.14. Despite the earnings miss, the stock rose by $0.56 to $26.25, and analysts largely maintain a "Moderate Buy" rating with a $34.18 average price target. Insider transactions show significant sales, while institutional investors hold 44.58% of the company.
California State Teachers Retirement System Has $2.44 Million Stock Position in Immunome, Inc. $IMNM
The California State Teachers Retirement System significantly increased its stake in Immunome, Inc. by 66.3% in the first quarter, now holding 111,444 shares valued at $2.44 million. Despite recent insider selling, institutional investors collectively own 44.58% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $34.18. Immunome recently reported a better-than-expected quarterly loss and is trading at $25.69.
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 15,248 Shares
Immunome (NASDAQ:IMNM) Director Isaac Barchas sold 15,248 shares of the company's stock on August 7th for over $397,000, reducing his direct holdings by 17.39%. This sale was part of a pre-arranged Rule 10b5-1 plan, and he has sold more than 320,000 shares since late June. Immunome's stock is trading near its 52-week high, and analysts maintain a "Moderate Buy" consensus with an average target price of $34.18.
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 20,840 Shares
Immunome (NASDAQ:IMNM) Director Isaac Barchas sold 20,840 shares of the company's stock on August 6th at an average price of $26.06, totaling over $543,000. This transaction was part of a Rule 10b5-1 plan and reduced his holdings by 19.21%. This sale is one of several made by Barchas since late June, totaling more than 300,000 shares.
Price to sales forward of Immunome, Inc. – NASDAQ:IMNM
This article displays the "Price to sales forward" metric for Immunome, Inc. (NASDAQ: IMNM) on TradingView. It presents financial data for the company, indicating the value, change, and percentage change for this specific financial ratio. The content is primarily a data point rather than an in-depth analysis.
Immunome CBO Kinney Horn sells $2.27m in company stock
Immunome's Chief Business Officer, Kinney Horn, sold 90,616 shares of company stock for $2.27 million after exercising employee stock options. This transaction occurred when the stock was near its 52-week high and followed a 162% gain over the past year. InvestingPro analysis suggests the stock is currently overvalued and in overbought territory.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 6, 2026
Immunome, Inc. announced that its Compensation Committee granted inducement awards consisting of non-statutory stock options to nine new employees. These awards, totaling 176,500 shares, were approved in accordance with Nasdaq Listing Rule 5635(c)(4) to incentivize employment. The stock options have an exercise price of $23.01 and will vest over four years, subject to continued employment.
Immunome (NASDAQ:IMNM) Insider Sells $2,273,555.44 in Stock
Immunome (NASDAQ:IMNM) insider Kinney Horn sold 90,616 shares of the company's stock for approximately $2.27 million on August 4th, reducing their direct ownership by 64.27%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. The clinical-stage biotechnology company, which focuses on antibody-based treatments for oncology and infectious diseases, has a "Moderate Buy" consensus rating from analysts with an average price target of $33.17.
Immunome CBO Kinney Horn sells $2.27m in company stock
Kinney Horn, CBO at Immunome Inc., sold 90,616 shares of company stock worth over $2.27 million on August 4, 2026, after exercising employee stock options. This sale occurred while the stock was near its 52-week high and followed a 162% gain over the past year. Horn now holds no direct beneficial ownership but retains options for 199,292 shares.
IMNM (IMNM) investor ABHMC II LLC plans sale of 108,504 common shares
ABHMC II LLC, an investor in Immunome Inc. (IMNM), plans to sell 108,504 common shares via Merrill Lynch on or after August 6, 2026. These shares, valued at approximately $2.77 million, were acquired through a private placement on October 3, 2023. The filing also details several previous sales of IMNM shares by ABHMC II LLC and ARSENAL BRIDGE VENTURE II-B LLC in the preceding three months.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. announced that its Compensation Committee granted inducement awards of non-statutory stock options to nine new employees on August 3, 2026. These options allow them to purchase an aggregate of 176,500 shares of common stock at an exercise price of $23.01 per share. The awards vest over four years and were made in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. announced that its Compensation Committee granted inducement awards to nine new employees on August 3, 2026. These awards consist of non-statutory stock options to purchase 176,500 shares of common stock, with an exercise price of $23.01 per share, vesting over four years. This action aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
Edgestream Partners L.P. Makes New $1.31 Million Investment in Immunome, Inc. $IMNM
Edgestream Partners L.P. has made a new $1.31 million investment in Immunome, Inc. (NASDAQ:IMNM), acquiring 59,888 shares. This investment highlights continued institutional interest, with other hedge funds also adjusting their positions, bringing total institutional ownership to 44.58%. Despite analyst recommendations for a "Moderate Buy" and a consensus price target of $33.17, the company remains unprofitable, and insiders have sold a significant number of shares recently.
Insider at IMNM (NASDAQ: IMNM) plans sale of 90,616 shares
Alfred K. Horn, an insider at Immunome Inc. (NASDAQ: IMNM), has filed a Form 144 notice to sell up to 90,616 shares of common stock on August 4, 2026, through Fidelity Brokerage Services LLC. This planned sale is in connection with a stock option exercise and has an aggregate value of $2,274,006.85. Horn also sold 1,092 shares for $27,300.00 on July 7, 2026, within the prior three months.
Price to earnings forward of Immunome, Inc. – NASDAQ:IMNM
This article provides a brief overview of Immunome, Inc. (NASDAQ: IMNM) financials, specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a section of a larger financial data page on TradingView, indicating that the detailed financial figures for the P/E forward metric are to be displayed within the specified period and value fields. It serves as a financial data point for the biotechnology company.
Immunome Inc (IMNM) Financial Health: Profitability & Balance Sheet Analysis
The article analyzes the financial health of Immunome Inc (IMNM), noting its robust financial status with a score of 7.15 out of 10, ranking 137th in the Biotechnology & Medical Research industry. Despite this, the company exhibits low operating efficiency, with recent quarterly revenue decreasing by 100% year-over-year and net profit declining by 29.30%. The report highlights that relevant data for several financial metrics like quality of earnings, operational efficiency, growth potential, and shareholder returns have not yet been disclosed by the company.
Immunome Inc (IMNM) Valuation: PE, PB & Fair Value Analysis
Immunome Inc (IMNM) currently has a valuation score of 8.36, placing it 136th out of 384 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -9.69, which is significantly below its recent high and slightly above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not been disclosed by the company.
(IMNM) Volatility Zones as Tactical Triggers
This article analyzes Immunome Inc. (NASDAQ: IMNM), identifying a mid-channel oscillation pattern and a strong risk-reward short setup. It details three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report also notes a near-term strong sentiment, leading to mid-term neutrality and a long-term positive bias for IMNM.
Aristotle Atlantic Partners LLC Makes New $2.73 Million Investment in Immunome, Inc. $IMNM
Aristotle Atlantic Partners LLC has made a new $2.73 million investment in Immunome, Inc. (NASDAQ:IMNM), purchasing 125,018 shares in the first quarter. This comes as several other institutional investors, including T. Rowe Price and Vanguard, also increased their stakes, with institutional ownership now standing at 44.58%. However, company insiders have been selling shares, with CFO Max Rosett and Director Isaac Barchas trimming their holdings, contributing to a total of 472,142 shares sold by insiders in the last 90 days.
Immunome Inc (IMNM) Institutional Confidence
Immunome Inc (IMNM) has an institutional shareholding score of 10.00, ranking 1st in the Biotechnology & Medical Research industry, with institutional ownership at 102.66%, up 21.95% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 0.06% of shares outstanding. Key institutional investors include Fidelity Management & Research Company LLC, T. Rowe Price Investment Management, Inc., and Point72 Asset Management, L.P., all of whom increased their holdings significantly.
Immunome Inc. (IMNM) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Immunome Inc. (IMNM) stock on NASDAQ, showing a current price of $22.67 with a gain of 2.07%. It indicates that information on analyst ratings and earnings is not currently available for Immunome Inc. The broader content of the page also includes extensive resources and disclaimers about stock trading, particularly penny stocks, and highlights the high risk and potential for losses in day trading.
Immunome, Inc. Revenue Breakdown – BOATS:IMNM
Immunome, Inc. (IMNM) generated $6.94 million in revenue last year, primarily from its Targeted Oncology Therapies segment. This figure is down from $9.04 million in the previous year. The United States was the greatest contributor to their revenue, accounting for the entire $6.94 million.
Immunome Inc (IMNM) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Immunome Inc (IMNM) stock, focusing on its dividend and stock split history. It indicates that Immunome Inc has not distributed any dividends over the past five years. The page also presents current stock data including market cap and recent price movements.
Immunome Inc (IMNM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Immunome Inc (IMNM), noting that relevant data for business segments, regional revenue, and profit contribution for several fiscal years (FY2023-FY2025) has not yet been disclosed by the company. It indicates a revenue of $6.94 million from the United States with 0.00% proportion.
IMNM|Immunome Inc|Price:22.220|Chg%:+0.210
This article provides a detailed financial overview of Immunome Inc (IMNM), including its stock price, market cap, and key financial indicators. It presents quarterly and annual data for income statements, balance sheets, and cash flow statements, offering insights into the company's revenue, net profit, assets, liabilities, and earnings per share. Additionally, it addresses frequently asked questions regarding Immunome Inc's financial performance based on its FY2025 earnings report.
Immunome, Inc. (IMNM) Stock Analysis: A 62% Potential Upside In The Biotech Arena
Immunome, Inc. (IMNM) is a US-based biotech firm focusing on antibody-drug conjugates and oncology therapeutics, with a market capitalization of $2.49 billion. Despite current financial challenges like negative EPS and no reported revenue growth, analysts project a 62.51% upside potential with an average target price of $35.77, driven by its promising clinical and preclinical pipeline. The company's stock is currently trading near oversold territory, which could signal a buying opportunity for risk-tolerant investors looking for growth in the volatile biotech sector.
Immunome, Inc. (IMNM) stock price, news, quote and history
This article provides a comprehensive overview of Immunome, Inc. (IMNM) stock, including its current price, key financial metrics, performance data, and analyst ratings. It details the company's biotechnology focus, pipeline of antibody-drug conjugates and oncology therapeutics, and lists comparative companies in the biotechnology industry.
